VAXX

Investor Moves

Name	Value	Action	Change	Price	Current Price
BlackRockInvestor $-1.9M ExitQ2 2024 $1.9M -- --
Jim SimonsRenaissance Technologies $-25 ExitQ2 2024 $25 -- --
Jim SimonsRenaissance Technologies $-25 ExitQ2 2024 $25 -- --

Trade VAXX

About Vaxxinity, Inc.

Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.

CEO: Mei Mei Hu
IPO Date: Nov 11, 2021

Market Data

Open: $0.02
High: $0.02
Low: $0.015
Volume: 257
Avg Volume: 17.2K
52W High: $0.20
52W Low: $0.0001

Valuation

Market Cap: $1.9M
Enterprise Value: $12M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-58M
Revenue: $0
Net Income: $-57k
Cash: $4.9M
Debt: $15M

Events

EarningsAug 12

EPS est. -0.12